Today, Triall announces the official release of the 2.0 version of the Triall whitepaper! This new version reflects our latest insights, plans, and vision for building towards the world’s first, blockchain-enabled digital ecosystem for clinical trials. An ecosystem that will comprise a multi-sided platform of modular, complementary, and interoperable software solutions for all types of clinical research professionals.
Triall was initiated to address several persistent issues that make the conduct of clinical trial operations overly complex, lengthy, and resource-inefficient. Our core mission is to accelerate the introduction of novel medical solutions to society by enabling a future of smarter, safer, and more-efficient clinical trials.
Bringing together a consortium of clinical operations experts, enterprise IT specialists, and blockchain developers, we are building towards the world’s first digital ecosystem for clinical trials that connects all types of clinical trial stakeholders: the Triall Ecosystem. It offers a series of modular applications that each tailor to identified unmet needs of clinical trial professionals, working with an API-driven infrastructure to selectively apply the strengths of blockchain and decentralized identity technologies where these truly add value.
What’s changed since version 1.0?
On the 17th of April 2019, almost exactly two years ago, we released the 1.0 version of the Triall whitepaper. Over the past 2 years, we managed to further develop and commercialize our first application Verial eTMF, which is now being used in multiple commercial clinical trial projects, and expand our international network of partners and advisors, which, among others, now includes industry-leading blockchain and crypto agency Applicature.
The 2.0 version of the Triall whitepaper reflects our latest insights, plans, and visions. Key changes include alterations to our token system and token allocation. To illustrate, we have designed a two-token system that next to our utility token TRL introduces a secondary token T-CRED. This secondary token is designed with the clinical trial professional in mind (i.e., the end-user of Triall solutions) as it provides them with predictable and stable costs. Moreover, we introduce loyalty programs for both clinical trial professionals (through Triall Memberships) and token holders (through TRL Community Rewards) where individuals/entities are rewarded for locking up their tokens. Another key addition to our whitepaper is the Triall Community Fund, an investment vehicle that will comprise 10% of the total TRL token supply, designed to sponsor and promote community-grown initiatives. Last but not least, we updated the roadmap, partners, and advisor sections, to display the growth and developments made over the past 2 years.
We recently opened up our Pre-sale campaign for institutional and retail investors. Those interested in joining our initiative are welcomed to register on our website (triall.io). Our token sale is now in full swing and the team has been working around the clock expanding our current network and community with synergetic partners, advisors, investors, and stakeholders that bridge the healthcare and crypto domains.
We’re presented with an incredible opportunity: We’re a first-mover in our industry, and are positioned to become a key ‘translational agent’ for blockchain technology in clinical trials. Blockchain provides a unique toolbox for our industry domain, enabling verifiable proof of data integrity, and securing and streamlining digital research activities. We see that our industry is digitalizing at a rapid pace, so these unique benefits of blockchain technology will only become more and more valuable in the future. We now have the means and the momentum to make a big positive impact, and we invite you to join us on this journey.
The new version of our whitepaper can be found here.